Vaxcyte Reports Positive Phase 3 Trial Results for Pneumococcal Vaccine VAX-31
Product·3 articles across 3 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Vaxcyte announced positive topline data from the OPUS-1 trial, a pivotal Phase 3 study for its 31-valent pneumococcal conjugate vaccine, VAX-31. The results exceeded Wall Street expectations, leading to a significant surge in the company's stock price.
The OPUS-1 trial's success positions Vaxcyte favorably in the competitive pneumococcal vaccine market, which includes established products like Prevnar. Analysts noted that the data represents a 'near best-case' scenario for the company, potentially enhancing its market position.
Vaxcyte
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate…”
SEC Filing — Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate…
AnalysisInterprets it
“Vaxcyte stock surged after its pneumococcal vaccine passed a key phase 3 test”
quartz — Vaxcyte stock surged after its pneumococcal vaccine passed a key phase 3 test
CommentaryOpinion